Study finds chemotherapy antidote could improve recovery after chemotherapy-induced kidney toxicity

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study. Using data from 28 major U.S. cancer centers, the researchers examined the association between glucarpidase treatment -- which rapidly clears MTX from the blood -- and outcomes of patients with MTX-induced acute kidney injury (AKI). They found that patients who received glucarpidase had significantly higher chances of kidney recovery compared to those who did not get this treatment.